セラノスティクス横浜がお届けする最新のセラノスティクス　セラヨコ・ライブラリー

Information
2025.03.24　
サイトを公開しました。

文献のご紹介　※セラヨコ・トーク付き

Low-and High- Volume Disease in Mertastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study

Journal of Nuclear Medicine January 2025, 66 (1) 54-60;
DOI 10.2967/
jnumed.124.268441

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2)Predicts Short Progression-Free Survival for PatientsUndergoing177 Lu-PSMA-I&T Therapy

J Nucl Med 2023; 64:410-415
DOI　10.2967/
jnumed.122.264677

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

DOI　10.1016/
S1470-2045(25)00009-9

Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery

DOI　10.2967/
jnumed.124.268151

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving　[177Lu]Lu PSMA-617

DOI　10.2967/
jnumed.124.268277

Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET/CT with an inter- and intrapatient based analysis

DOI　10.1186/
s13550-024-01097-3

Is Routine Dosimetry Really Happening?

DOI　10.2967/
jnumed.124.267830

※セラヨコ・トーク＝抄読会でのセラヨコメンバーのつぶやき

動画コンテンツ